In Ba/F3-BCR-JAK2 cells carrying pLZR with BCR-JAK2, TG101209 at 1 µM produced a 76% inhibition rate of BCR-JAK2 phosphorylation at 12 h compared with the vehicle (DMSO). In the same cell model carrying pLZR with BCR-JAK2, treatment at 1 µM for 24 h increased Annexin-V/7-AAD–positive cells by approximately 80% compared with DMSO. In RAW264.7 macrophages, TG101209 exhibited no significant cytotoxicity at concentrations below 5 μM within 24 hours. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
BCR-JAK2 phosphorylation inhibition in Ba/F3-BCR-JAK2 cells
Cell-based study · Ba/F3-BCR-JAK2 cells [1]
In Ba/F3-BCR-JAK2 cells carrying pLZR with BCR-JAK2, treatment at 1 µM for 12 h produced a 76% inhibition rate of BCR-JAK2 phosphorylation compared with the vehicle (DMSO).
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 µM
- Exposure duration
- 12 h
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: pLZR carrying BCR-JAK2. Compound effect isolated by the comparison: the vehicle (DMSO).
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: TG101209
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > TG101209 abrogated BCR-JAK2 activation and STAT5 phosphorylation leading to downregulation of STAT5 target gene transcription (S113, S115); Figure 2 legend (S165); Figure 4 legend (S185, S186)
BCR-JAK2 phosphorylation: BCR-JAK2 phosphorylation; comparator: the vehicle (DMSO) — Results > TG101209 abrogated BCR-JAK2 activation and STAT5 phosphorylation leading to downregulation of STAT5 target gene transcription (S113)
Cytotoxicity assessment in RAW264.7 macrophages
Cell-based study · RAW264.7 macrophages [2]
In RAW264.7 macrophages, TG101209 exhibited no significant cytotoxicity at concentrations below 5 μM within 24 hours.
Literature-Reported Treatment Conditions
- Treatment concentration
- below 5 μM
- Exposure duration
- within 24 hours
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: TG101209
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > TG101209 regulates macrophage polarization in vitro (S25, S26); Materials and methods > Cell viability assay (S54)
cytotoxicity: cytotoxicity; comparator: control optical density — Results > TG101209 regulates macrophage polarization in vitro (S26)
Increased annexin-positive cells in Ba/F3-BCR-JAK2 cultures
Cell-based study · Ba/F3-BCR-JAK2 cells [1]
In Ba/F3-BCR-JAK2 cells carrying pLZR with BCR-JAK2, treatment at 1 µM for 24 h increased Annexin-V/7-AAD–positive cells by approximately 80% compared with DMSO.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 µM
- Exposure duration
- 24 h
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: pLZR carrying BCR-JAK2. Compound effect isolated by the comparison: DMSO.
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: TG101209
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Apoptosis analysis by flow cytometry (S63); Results > TG101209 induces Ba/F3-BCR-JAK2 cell death by apoptosis (S123); Figure 2 legend (S165); Figure 5 legend (S195, S197)
Apoptosis was measured using flow cytometry analysis as the percentage of cells expressing annexin-V/7-AAD on the cell surface.: Apoptosis was measured using flow cytometry analysis as the percentage of cells expressing annexin-V/7-AAD on the cell surface.; comparator: DMSO — Results > TG101209 induces Ba/F3-BCR-JAK2 cell death by apoptosis (S123); Figure 5 legend (S197)